BioNova Acquires Rights to CD74 Candidate from Sutro in $204 Million Deal
October 12, 2021 at 05:23 AM EDT
Shanghai BioNova Pharma acquired an option for China rights to a CD74 antibody drug candidate for hematologic cancers from South San Francisco 's Sutro Biopharma in a $204 million agreement. BioNova will make a $4 million payment for the option, and it will pay up to $200 million to exercise the option and make milestone payments. It will develop STRO-001 to treat non-Hodgkin's lymphoma, multiple myeloma and leukemia. Sutro will also receive tiered, double-digit royalties. More details.... Stock Symbol: (NSDQ: STRO) Share this with colleagues: // //
